ReviewPostepy dermatologii i alergologii2026
Lebrikizumab for the treatment of atopic dermatitis: a systematic review and meta-analysis of randomised controlled trials.
Review in Postepy dermatologii i alergologii, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Atopic dermatitis (AD) is a chronic inflammatory disease. Lebrikizumab has emerged as a potential therapeutic strategy, but their efficacy and safety profile in patients with atopic dermatitis requires comprehensive evaluation. Aim: To evaluate the efficacy and safety of lebrikizumab in the treatment of AD and to provide evidence-based guidance for clinical use. Methods: PubMed, Embase, Web of Science, Medline, and ClinicalTrials.gov were systematically searched for randomised controlled trials (RCTs) comparing lebrikizumab (experimental group) with placebo (control group) from database inception to December 2025. After literature screening and data extraction, the quality of included studies was assessed using the bias risk assessment tool recommended in the Cochrane Handbook for Systematic Reviews of Interventions (Version 5.1.0). Meta-analysis was performed using RevMan 5.4 software, while sensitivity analysis and publication bias analysis were conducted using Stata software. Results: A total of 7 studies comprising 7 RCTs with 2168 patients were included. Meta-analysis results showed that patients in the experimental group had significantly higher rates of EASI 75 (OR = 3.65, 95% CI (2.58, 5.16), Conclusions: Lebrikizumab demonstrates favourable efficacy and safety in the treatment of AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.